# Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis

> **NCT00376129** · PHASE2 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 10 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Alefacept

## Key facts

- **NCT ID:** NCT00376129
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2007-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00376129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00376129, "Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00376129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*